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        Introduction 
  Src is an important regulatory protein that functions in several 
fundamental processes, including cell differentiation, prolifera-
tion, migration, and survival (  Summy and Gallick, 2003  ,   2006  ; 
  Frame, 2004  ;   Playford and Schaller, 2004  ;   Russello and Shore, 
2004  ;   Yeatman, 2004  ). Because of its prominent roles in cell 
signaling, aberrant Src activation, which is frequently found in 
common human cancers such as colon cancer (  Rosen et al., 
1986  ;   Bolen et al., 1987  ;   Cartwright et al., 1989  ,   1990  ;   Aligayer 
et al., 2002  ), is considered a key factor in cancer progression. 
Thus, inhibition of Src represents a promising approach for can-
cer therapy. Indeed, a large number (  >  50 at last count) of Src 
inhibitor  –  based clinical trials have been initiated (  Kopetz et al., 
2007  ). However, despite the wealth of information on the struc-
tural basis and functional consequences of Src activation 
(  Thomas and Brugge, 1997  ), how Src is activated in cancer cells 
remains largely elusive. 
  Reversion-induced LIM (RIL) is a ubiquitously expressed 
protein that was initially identifi  ed during a search for genes 
that are expressed in normal cells but repressed in Harvey ras  –
  transformed derivatives (  Kiess et al., 1995  ). The expression of 
  RIL   is restored in several independent phenotypic revertants de-
rived from Harvey ras  –  transformed cells (thus, it was named as 
reversion-induced LIM). Recent experiments have shown that 
  RIL   is a target of epigenetic silencing (  Boumber et al., 2007  ). 
Hypermethylation of   RIL   was found in a large number of can-
cer cell lines and tumors derived from various origins, including 
the colon, liver, and breast (  Boumber et al., 2007  ). Fur  ther  more, 
  RIL   transcription is suppressed in multiple types of human 
cancer cells, including colon cancer cells, and reexpression of 
RIL inhibited anchorage-independent growth (  Boumber et al., 
2007 ).  These  fi  ndings strongly suggest that loss of RIL con-
tributes to malignant behavior. However, the underlying mo-
lecular mechanism is not known. In this study, we show that 
RIL mediates a novel Src inactivation cycle and, thus, that loss 
of RIL promotes Src activation and consequently anchorage-
independent growth. 
  Results and discussion 
 We  fi  rst verifi  ed that the expression of RIL protein was inhib-
ited in human colon cancer cells. To do this, we generated an 
mAb specifi  cally recognizing RIL. Western blotting analyses 
of HCT116 (  Fig. 1 A  , lane 2), HT29 (  Fig. 1 A  , lane 3), RKO 
(  Fig. 1 A  , lane 4), Caco-2 (  Fig. 1 A  , lane 5), and DLD-1 (  Fig. 1 A  , 
lane 6) colon cancer cells showed that they all lacked RIL. Addi-
tionally, no RIL was detected in several other types of cancer 
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of Y530 (Y527 in chickens) phosphorylation, which inhibits 
Src activity (  Roskoski, 2005  ), was slightly increased (by a mean 
of 7.6   ±   4.4%; mean   ±   SD;   n   = 3; P = 0.038) in response to RIL 
expression (  Fig. 1 B  ). The level of total Src was not changed 
(  Fig. 1 B  ). To directly test whether RIL inhibits Src activation, 
we immunoprecipitated Src from RIL-expressing (  Fig. 1 C  , 
lane 2) and RIL-null control (  Fig. 1 C  , lane 1) cells. Consistent 
with the suppression of Y419 phosphorylation, the activity of 
Src isolated from the RIL-expressing cells was signifi  cantly 
lower than that of RIL-null control cells (  Fig. 1 D  ). To further 
test this, we analyzed Y576/577 phosphorylation of FAK, an in 
vivo substrate of Src, and found that it was substantially reduced 
in response to the expression of RIL (  Fig. 1 E  ). Collectively, 
these results suggest that RIL plays an important role in the 
suppression of Y419 phosphorylation and consequently the 
  inactivation of Src. 
cells, including HeLa (  Fig. 1 A  , lane 8) and 293 (  Fig. 1 A  , lane 9) 
cells. The lack of signals in the RIL Western blots was not the 
result of technical issues with the anti-RIL mAb or the sam-
ples, as RIL was readily detected in other cells (  Fig. 1 A ,  lanes 
1 and 7) and tubulin was detected in all samples (  Fig. 1 A  ). 
Thus, consistent with the epigenetic experiments showing hyper-
methylation of   RIL   (  Boumber et al., 2007  ), colon cancer cells 
lack RIL protein. 
 The  fi  nding that RIL expression is suppressed in human 
colon cancer cells, in which Src is known to be aberrantly acti-
vated, prompted us to test whether RIL plays a role in Src in-
activation. To do this, we expressed RIL in human HCT116 colon 
cancer cells (  Fig. 1 B  , lane 2). Phosphorylation of Y419 (Y416 
in chickens) in the activation loop, which is essential for full 
activation of Src (  Roskoski, 2005  ), was markedly reduced (by 
48.2   ±   20.1%; mean   ±   SD;   n   = 6; P   <   0.001), whereas the level 
  Figure 1.       RIL inhibits Src activation and re-
duces anchorage-independent growth.   (A) Ly-
sates (15   μ  g/lane) of WI-38 (lane 1), HCT116 
(lane 2), HT29 (lane 3), RKO (lane 4), Caco-2 
(lane 5), DLD-1 (lane 6), SK-LMS-1 (lane 7), 
HeLa (lane 8), and 293 (lane 9) cells were 
analyzed by Western blotting with antibodies 
recognizing RIL or tubulin (as a loading con-
trol). (B) HCT116 cells were transfected with 
Flag-RIL vector (lane 2) or a vector lacking the 
RIL sequence as a control (lane 1). The lysates 
were probed with antibodies recognizing 
RIL, Src, pY419 Src, or pY530 Src. (C) Src 
was immunoprecipitated from HCT116 cells 
transfected with the control (lane 1) or Flag-RIL 
(lane 2) vector and analyzed by Western blot-
ting with an anti-Src antibody. (D) The kinase 
activity of Src derived from the Flag-RIL trans-
fectants was compared with that of the control 
cells. (E) FAK was immunoprecipitated from 
HCT116 cells transfected with the control (lane 1) 
or Flag-RIL (lane 2) vector and analyzed by 
Western blotting with antibodies speciﬁ  c  for 
FAK or pY566/577 FAK. IP, immunoprecip-
itation. (F) Anchorage-independent growth 
of HCT116 cells in the presence of PP2 or 
PP3 was compared with that of HCT116 cells 
grown in the absence of PP2 and PP3 (con-
trol). (G and H) HCT116 cells were transfected 
with the control vector (G, lane 1), the Flag-RIL 
vector (G, lane 2), or the Flag-RIL vector and 
a vector encoding a constitutively active form 
of chicken Src (Y527F; G, lane 3). (G) The 
lysates were probed with antibodies recogniz-
ing RIL, pY419 Src, or Src. (H) Anchorage-
independent growth of the cells expressing 
Flag-RIL or Flag-RIL and constitutively active Src 
was compared with that of the control cells. 
(D, F, and H) Error bars represent mean   ±   SD 
(  n   = 3). Mr, molecular mass.     787 A NOVEL SRC INACTIVATION CYCLE   • Zhang et al. 
purifi  ed Src with GST-RIL and found that it did not reduce the 
kinase activity (  Fig. 3 A  ). Thus, RIL binding alone is insuffi  -
cient for Src inactivation. To test the second possibility, we 
immunoprecipitated Flag-RIL (  Fig. 3 B  , lane 2) and analyzed 
associated phosphatase activity. A signifi  cantly higher phos-
phatase activity was detected in Flag-RIL immunoprecipitates 
compared with that of the control immunoprecipitates (  Fig. 3 C  ). 
Deletion of the LIM domain or the second zinc fi  nger within 
the LIM domain signifi  cantly reduced the phosphatase activity 
( Fig.  3  D ). 
  What is the molecular identity of the phosphatase involved 
in RIL-mediated Src inactivation? Protein Tyr phosphatase 
(PTP)  –  BAS-like (BL), a mouse homologue of human PTPL1, 
was previously found to interact with RIL (  Cuppen et al., 1998  ), 
albeit the function of this interaction is unknown. The catalytic 
sequence of PTPL1 was identifi  ed as an Src antagonizer in a 
functional screen in yeast (  Superti-Furga et al., 1996  ). In vitro, 
PTP-BL phosphatase domain can catalyze pY419 dephosphory-
lation (  Palmer et al., 2002  ). Based on these fi  ndings, we hypoth-
esized that RIL promotes dephosphorylation of pY419 through 
recruitment of PTPL1. Up to now, the interaction of PTP-BL 
with RIL was demonstrated only with recombinant PTP-BL 
fusion protein. Thus, we sought to test whether RIL forms a 
complex with endogenous PTPL1 in mammalian cells. The re-
sults showed that endogenous PTPL1 was readily coimmuno-
precipitated with Flag-RIL (  Fig. 3 E  , lane 6) but not with control 
precipitates lacking RIL (  Fig. 3 E  , lane 5), confi  rming the inter-
action of PTPL1 with Flag-RIL in cells. 
  Next, we sought to test whether PTPL1 binding is required 
for RIL-induced pY419 dephosphorylation. Deletion of LIM 
(    LIM) or the second zinc fi  nger (    ZF2) eliminated the PTPL1 
binding (  Fig. 3 E  , lanes 7 and 8). Importantly, expression of the 
PTPL1 binding – defective   LIM (not depicted) or   ZF2 ( Fig. 3 F , 
lane 3) mutant, unlike that of wild-type RIL (  Fig. 3 F  , lane 2), 
failed to inhibit Y419 phosphorylation. These results suggest that 
the interaction with PTPL1 is required for RIL-mediated de-
phosphorylation of pY419. 
  To further test our hypothesis that RIL promotes pY419 de-
phosphorylation through PTPL1, we depleted PTPL1 by RNAi 
( Fig. 3, G and H , lanes 3 and 4). Flag-RIL was expressed in PTPL1 
knockdown cells (  Fig. 3, G and H  , lane 3) as well as in control 
cells expressing a normal level of PTPL1 ( Fig. 3, G and H , lane 2). 
As expected, expression of Flag-RIL substantially reduced Y419 
phosphorylation in control cells (  Fig. 3, G and H  , lane 2). By 
marked contrast, expression of Flag-RIL failed to inhibit Y419 
phosphorylation in the absence of PTPL1 (  Fig. 3, G and H  , lane 3). 
Although knockdown of PTPL1 from RIL-expressing cells mark-
edly increased Y419 phosphorylation (  Fig. 3, G and H  , compare 
lane 2 with lane 3), the effect of PTPL1 knockdown on Y419 
phosphorylation was noticeably diminished in the absence of RIL 
(  Fig. 3, G and H  , compare lane 1 with lane 4). Collectively, these 
results provide strong evidence suggesting that RIL suppresses 
Src activation by physically linking PTPL1 to Src and conse-
quently promoting pY419 dephosphorylation. 
  Next, we tested the effect of Src inactivation on RIL bind-
ing. Treatment of Src with PP2, a pyrazolo pyrimidine-type 
inhibitor that is known to lock Src in an inactive conformation 
  Src is known to play a role in the regulation of anchorage-
independent growth (  Summy and Gallick, 2003  ,   2006 ;   Frame, 
2004  ;   Playford and Schaller, 2004  ;   Russello and Shore, 2004  ; 
  Yeatman, 2004  ). Consistent with this, treatment of HCT116 cells 
with the Src inhibitor PP2 but not with PP3 (a PP2 analogue 
lacking Src inhibitory activity) reduced anchorage-independent 
growth (  Fig. 1 F  ). Expression of Flag-RIL, like treatment of cells 
with PP2, signifi  cantly reduced anchorage-independent growth 
(  Fig. 1 H  ). Importantly, RIL-induced inhibition of anchorage-
independent growth was substantially reversed (  Fig. 1 H  ) in 
response to expression of a constitutively active Src (  Fig. 1 G  , 
lane 3), suggesting that RIL inhibits anchorage-independent 
growth at least partly through the suppression of Src activation. 
  Next, we sought to determine the mechanism by which 
RIL suppresses Src activation. A fraction of RIL colocalized 
with Src, particularly in the perinuclear areas (  Fig. 2, A  –  C  ). Con-
sistent with a role of RIL in Src inactivation, RIL was undetect-
able in areas where high concentrations of phospho-Y419 
(pY419) Src (i.e., active Src) were present (  Fig. 2, D  –  F  ). The 
fi  nding that a fraction of Src colocalizes with RIL (  Fig. 2, A  –  C  ) 
prompted us to test whether Src physically interacts with RIL. To 
do this, we generated a maltose-binding protein (MBP)  –  tagged 
Src protein and found that it was coprecipitated with GST-RIL 
(  Fig. 2 G  , lane 3) but not with GST ( Fig. 2 G  , lane 2). Probing the 
same samples with an anti-pY419 Src antibody revealed that 
pY419 Src was enriched in the GST-RIL precipitates. To further 
analyze the binding, we generated GST-tagged Src and MBP-
tagged RIL. MBP-RIL was coprecipitated with GST-Src ( Fig. 2 H , 
lane 3) but not GST (  Fig. 2 H  , lane 2), confi  rming the interaction 
between the two proteins. To identify Src domains that mediate 
RIL binding, we generated GST fusion proteins containing the 
SH3 (residues 88  –  149), SH2 (residues 150  –  248), or kinase (resi-
dues 249  –  536) domains of Src. MBP-RIL was coprecipitated 
with GST kinase domain (  Fig. 2 H  , lane 5) but not with GST-
SH3 (  Fig. 2 H  , lane 7). A smaller amount of MBP-RIL was also 
coprecipitated with GST-SH2 (  Fig. 2 H  , lane 9). Thus, the kinase 
domain and, to a lesser extent, the SH2 domain but not the SH3 
domain mediate the interaction with RIL. 
  To test whether RIL forms a complex with Src in cells, 
we immunoprecipitated Flag-RIL from Flag-RIL  –  expressing 
HCT116 cells (  Fig. 2 I  , lane 3). Src was readily coimmuno-
precipitated with Flag-RIL (  Fig. 2 I  , lane 3). In control experi-
ments, no Src was detected in anti-Flag immunoprecipitates 
derived from control transfectants lacking Flag-RIL (  Fig. 2 I  , 
lane 2). To further test this, we immunoprecipitated endogenous 
RIL from WI-38 cells. Again, Src was readily coimmuno-
precipitated with RIL (  Fig. 2 J  , lane 3). Thus, consistent with the 
colocalization (  Fig. 2, A  –  C  ) and direct binding (  Fig. 2, G and H  ) 
experiments, RIL forms a complex with Src in cells. 
 The  fi  nding that RIL binds Src suggested two potential 
mechanisms by which RIL could suppress Src activation. First, 
RIL binding could potentially interfere with conformation 
changes involved in Src activation and thereby suppresses Src 
activation. Alternatively, RIL could function as an adapter pro-
tein for a protein phosphatase and consequently link the phos-
phatase to Src and promote pY419 dephosphorylation, resulting 
in Src inactivation. To test the fi  rst possibility, we incubated JCB • VOLUME 184 • NUMBER 6 • 2009  788
tion loop and thereby inhibits full activation of Src (  Kmiecik 
and Shalloway, 1987  ;   Piwnica-Worms et al., 1987  ;   Ferracini 
and Brugge, 1990 ). Again, although wild-type Src readily bound 
to GST-RIL (  Fig. 4 B  , lane 4), substitution of Y419 with Phe 
eliminated the ability of Src to interact with GST-RIL (  Fig. 4 B  , 
lane 6). In control experiments, neither Src nor Y419F bound to 
GST (  Fig. 4 B  , lanes 3 and 5), confi  rming the specifi  city of the 
(  Schindler et al., 1999  ), abolished the ability of Src to bind RIL 
(  Fig. 4 A  , compare lane 5 with lane 6), suggesting that the in-
teraction between Src and RIL is negatively regulated by Src 
inactivation. This is consistent with the result of our binding 
experiments showing that pY419 Src was preferentially pulled 
down by RIL (  Fig. 2 G  ). To directly test this, we substituted 
Y419 with Phe, which prevents phosphorylation at the activa-
  Figure 2.       RIL colocalizes and interacts with Src.   
(A  –  F) WI-38 cells were dually stained with anti-RIL 
mAb 2A2.11 (A and D) and rabbit anti-Src (B) 
or anti-pY419 Src (E) antibodies. C and F show 
merged images. (G) 312.5 ng MBP-Src was incu-
bated with GST or GST-RIL as indicated. The input 
(lane 1; 10 ng/lane), GST (lane 2), and GST-RIL 
(lane 3) pull-downs were analyzed by Western 
blotting and Coomassie blue staining. (H) 250 ng 
MBP-RIL was incubated with GST or GST fusion 
protein containing Src SH3, SH2, or kinase do-
main (KD) as indicated. The input (lane 1; 2 ng/
lane) and GST or GST fusion protein pull-downs 
(lanes 2  –  10) were analyzed by Western blotting 
and Coomassie blue staining. (I) 250   μ  g of lysates 
of HCT116 cells transfected with Flag-RIL or the 
control vector were mixed with 20   μ  l of M2-
conjugated agarose beads. Lane 1 was loaded with 
5   μ  g of the control cell lysates (to show the position 
of Src). The immunoprecipitates were analyzed by 
Western blotting with anti-Src or anti-Flag antibod  ies. 
(J) Anti-RIL immunoprecipitates were prepared by 
mixing 500   μ  g WI-38 cell lysates with 5   μ  g anti-
RIL mAb. The lysates (lane 1; 5   μ  g/lane) and anti-
RIL immunoprecipitates (lane 3) were anal  yzed by 
Western blotting with anti-Src or anti-RIL antibodies. 
The sample in lane 2 was prepared as in lane 3 
except the lysates were omitted (to show the IgG 
bands derived from the anti-RIL antibody used in 
immunoprecipitation). Mr, molecular mass; WB, 
Western blot; IP, immunoprecipitation. Bar, 15   μ  m.     789 A NOVEL SRC INACTIVATION CYCLE   • Zhang et al. 
Y419F nor Y419F was coprecipitated with GST (  Fig. 4 C  , lanes 
5 and 7). Collectively, our fi  ndings suggest a model for RIL-
mediated inactivation of Src (  Fig. 5  ). In this model, RIL pref-
erentially recognizes active (i.e., pY419) Src. The binding of RIL 
to pY419 Src brings it to PTPL1 (  Fig. 5 A  , step 1), which catalyzes 
pY419 dephosphorylation. Dephosphorylation of Src at Y419 
shifts the balance toward an inactive conformation (similar to the 
PP2-bound autoinhibited form of Src [  Schindler et al., 1999  ] 
binding assay. To further test this, we substituted Pro302 and 
Pro307 (Pro299 and Pro304 in chickens) in the Y419F mutant 
with Glu, which is known to convert the Y419F mutant into an 
active kinase ( Gonfl  oni et al., 2000 ). The kinase-active Pro302E/ 
Pro307E/Y419F mutant (  Fig. 4 C  , lane 6), unlike the Y419F 
kinase-defective mutant (  Fig. 4 C  , lane 8), was coprecipitated 
with GST-RIL, confi  rming that RIL preferentially recognizes 
active Src. In control experiments, neither Pro302E/Pro307E/
  Figure 3.       PTPL1 mediates RIL-induced Src inactivation.   (A) The kinase activity of Src in the presence of GST-RIL was compared with that in the presence of 
the GST control (normalized to 100%;   n   = 2). (B) Anti-Flag immunoprecipitates were prepared from HCT116 cells transfected with the control vector (lane 1) 
or vectors encoding Flag-RIL (lane 2), Flag-    LIM (lane 3), or Flag-    ZF2 (lane 4) and analyzed by Western blotting with anti-Flag antibody. (C) Phospha  tase 
activities associated with Flag-RIL and control immunoprecipitates were measured as described in Materials and methods (  n   = 4). (D) Phosphatase activities 
associated with Flag-    LIM, Flag-    ZF2, or control immunoprecipitates were compared with those associated with Flag-RIL (normalized to 100%;   n   = 4). 
(E) Anti-Flag immunoprecipitates were prepared by mixing 700   μ  g cell lysates with 20   μ  l of M2-conjugated agarose beads. The lysates (lanes 1  –  4; 
15   μ  g/lane) and immunoprecipitates were analyzed by Western blotting with anti-PTPL1 or anti-Flag antibodies. (F) HCT116 cells were transfected with the 
control (lane 1), Flag-RIL (lane 2), or Flag-    ZF2 (lane 3) vector and analyzed by Western blotting with antibodies as indicated. (G and H) HCT116 cells 
were transfected with the Flag-RIL vector (lanes 2 and 3), the control vector (lanes 1 and 4), control RNA (lanes 1 and 2), and PTPL1 siRNA-1 (G) or -2 
(H; lanes 3 and 4) as indicated. The cells were analyzed by Western blotting with antibodies recognizing PTPL1, pY419 Src, Src, Flag, or tubulin. Note 
that RIL inhibits Y419 phosphorylation in cells that express a normal level of PTPL1 (lane 2) but not in PTPL1 knockdown cells (lane 3). (A, C, and D) Error 
bars represent mean   ±   SD. Mr, molecular mass; IP, immunoprecipitate.     JCB • VOLUME 184 • NUMBER 6 • 2009  790
or that of the Y419F mutant), which markedly reduces RIL 
binding and thus helps to release Src from the RIL  –  PTPL1 com-
plex (  Fig. 5 A  , step 2). The free RIL  –  PTPL1 complex can then 
bind to another pY419 Src and start a new cycle of pY419 
dephosphorylation (  Fig. 5 A  , step 3). This Src-inactivating cycle 
counterbalances Src-activating cycles and helps to keep the level 
of active Src in check in normal cells. Thus, in subcellular 
compartments in which this RIL-mediated Src inactivation cycle 
operates, Src activation is suppressed, whereas in areas lacking 
RIL (e.g., focal adhesions), the level of active Src is elevated. 
This is highly consistent with our subcellular localization experi-
ments (  Fig. 2, A  –  F  ) in which high levels of active Src were de-
tected in areas lacking RIL (e.g., focal adhesions) but not in areas 
where RIL was present. Similarly, in cells (e.g., colon cancer 
cells) in which RIL is lost as a result of epigenetic silencing, this 
Src inactivation mechanism is broken, resulting in aberrantly 
high levels of active (i.e., pY419) Src (  Fig. 5 B  ) and thereby con-
tributing to malignant behavior (e.g., anchorage-independent 
growth). Our experiments suggest a mechanism through which 
epigenetic silencing of   RIL   is linked to increased Src activation 
in colon cancer. Loss of this RIL  –  PTPL1-mediated Src inactiva-
tion cycle in colon cancer cells may provide an explanation as to 
why vanadate, a phosphatase inhibitor, can activate Src in normal 
colon cells but not in colon cancer cells (  DeSeau et al., 1987  ). 
Additionally, our fi  nding that PTPL1 is required for RIL-mediated 
Src inactivation may explain how epigenetic silencing or genetic 
mutations in   PTPN13   (the PTPL1 gene), which are frequently 
found in multiple types of human cancers such as colon cancer 
(  Wang et al., 2004  ;   Yeh et al., 2006  ;   Ying et al., 2006  ), could con-
tribute to malignant transformation. 
  In summary, we have demonstrated that RIL functions 
as an activation-dependent binding protein of Src and medi-
ates a novel Src inactivation cycle. The experiments present in 
this study shed light on the molecular mechanism underlying 
aberrant Src activation that has been frequently observed in 
colon and other human cancers. Given the prominent role of 
  Figure 4.       Inactivation of Src inhibits RIL interaction.   (A) 300 ng MBP-Src 
was pretreated with (lanes 2, 4, and 6) or without (lanes 1, 3, and 5) 
PP2 and then incubated with GST-RIL or GST. The inputs (lanes 1 and 2; 
5 ng/lane), GST precipitates (lanes 3 and 4), or GST-RIL precipitates (lanes 
5 and 6) were analyzed by Western blotting and Coomassie blue staining. 
(B) 250 ng MBP-Src or 250 ng MBP-Y419F was incubated with GST-RIL or GST. 
The inputs (lanes 1 and 2; 10 ng/lane), GST precipitates (lanes 3 and 5), or 
GST-RIL precipitates (lanes 4 and 6) were analyzed by Western blotting and 
Coomassie blue staining. The sample in lane 7 was prepared as that in lane 
4 except that MBP-Src was omitted. (C) 312.5 ng MBP-Y419F or 312.5 ng 
MBP-Pro302E/Pro307E/Y419F was incubated with GST-RIL or GST as in-
dicated. The inputs (lanes 1 and 2; 10 ng/lane), GST (lanes 5 and 7), or 
GST-RIL (lanes 6 and 8) precipitates were analyzed by Western blotting 
and Coomassie blue staining. Lanes 3 and 4 were loaded with GST 
and GST-RIL pull-downs prepared in the absence of MBP-Y419F or MBP-
Pro302E/Pro307E/Y419F. Mr, molecular mass; WB, Western blot.     
  Figure 5.       A model of RIL  –  PTPL1    -mediated Src inactivation.   (A and B) 
Schematic representations of a RIL  –  PTPL1-mediated Src inactivation cycle 
(A) and the effect of loss of RIL or PTPL1 on Src activation (B).     791 A NOVEL SRC INACTIVATION CYCLE   • Zhang et al. 
Src fusion proteins in a GST fusion protein pull-down assay. DNA frag-
ments encoding RIL or Src sequences as speciﬁ  ed in each experiment 
were prepared by PCR and inserted into the pGEX-5x-1 vector (GE 
Healthcare) or the pMAL-C2 vector (New England Biolabs, Inc.). Point 
mutations were introduced into the Src coding sequence using a Quik-
Change Site-Directed Mutagenesis system (Agilent Technologies). The re-
combinant vectors were used to transform   Escherichia coli   cells. The 
expression of the GST and MBP fusion proteins was induced with IPTG, 
and they were puriﬁ   ed by afﬁ   nity chromatography using glutathione  –
  Sepharose 4B and amylose-agarose, respectively, as we previously de-
scribed (  Tu et al., 2003  ). To test the interaction between GST-RIL and 
MBP-Src proteins, glutathione  –  Sepharose 4B beads containing GST-RIL or 
GST were preincubated with PBS containing 1% (vol/vol) Triton X-100 
and 1 mg/ml BSA. The beads were then incubated with 1   μ  g/ml of MBP-
tagged wild-type or mutant forms of Src at 4  °  C for 2 h and washed ﬁ  ve 
times with 1  ×   PBS/1% Triton X-100. To test the interaction between GST-
Src and MBP-RIL proteins, glutathione  –  Sepharose 4B beads containing 
GST, GST-tagged wild-type, or mutant forms of Src were preincubated 
with PBS containing 1% (vol/vol) Triton X-100 and 1 mg/ml BSA and 
were incubated with MBP-RIL. The samples were analyzed by Western 
blotting and Coomassie blue staining as speciﬁ  ed in each experiment. 
  Anchorage-independent growth 
  Anchorage-independent growth was determined using a soft agar colony 
formation assay as previously described (  Kolligs et al., 1999  ). In brief, 
HCT116 cells were transfected with the Flag-RIL vector, the Flag-RIL vector 
and a vector encoding the constitutively active Y527F mutant of chicken Src, 
or the Flag vector lacking the RIL sequence as a control. 1 d after the transfec-
tion, the cells were trypsinized and resuspended in culture medium. Under-
layers of 0.6% agar medium were prepared in 12-well plates at 0.5 ml/well 
by combining equal volumes of 1.2% SeaPlaque agarose (FMC BioProducts) 
and McCoy  ’  s 5A containing 10% FBS. The cells were washed three times 
with the culture medium and seeded in 12-well plates at 4,000 cells/well in 
0.3% SeaPlaque agarose. After incubation at 37  °  C in 5% CO  2   for 2 wk, 
colonies with diameters   >  0.5 mm were counted. The numbers of colonies in 
each microscopic ﬁ  eld (113 mm 
2  /ﬁ  eld) were calculated by analyzing at 
least six microscopic ﬁ  elds. Colony formation from cells expressing Flag-RIL 
or Flag-RIL and the constitutively active Src was compared with that of the 
control cells (presented as percentages of the control cells). The effect of PP2 
on anchorage-independent growth was analyzed using the aforementioned 
protocol except that HCT116 cells were grown in the presence of 10   μ  M PP2, 
10   μ  M PP3 (a PP2 analogue that lacks Src inhibitory activity), or neither PP2 
nor PP3 (control). Colony formation from cells grown in the presence of 
PP2 or PP3 was compared with that of the control cells (presented as percent-
ages of the control cells). 
  Src phosphorylation 
  pY419 or pY530 Src was detected by Western blotting with antibodies 
speciﬁ  c for the corresponding forms of Src. The densities of pY419 or pY530 
Src were quantiﬁ  ed by densitometry analysis using the Scion Image pro-
gram (National Institutes of Health). 
  Src kinase assays 
  The effect of RIL binding on Src kinase activity was analyzed using an 
HTScan(r) Src Kinase Assay kit (Cell Signaling Technology) according to the 
manufacturer  ’  s protocol. In brief, 2 ng/  μ  l GST-Src was incubated with GST-
RIL or GST at room temperature for 30 min. The samples were incubated 
with the substrate peptide for 30 min and mixed with an equal volume of 
50 mM EDTA to stop the reaction. The reaction solutions were transferred 
into 96-well streptavidin plates (Millipore) at 25   μ  l/well, diluted with 75   μ  l 
H  2  O, and incubated at room temperature for 60 min. At the end of the in-
cubation, the wells were rinsed three times with 0.1% Triton X-100 in PBS 
and incubated with anti  –  phospho-Tyr antibody pY-100 (1:1,000 dilution) 
for 60 min. After washing three times with 0.1% Triton X-100 in PBS, the 
wells were incubated with HRP-conjugated goat anti  –  mouse IgG antibody 
(1:1,000 dilution) for 60 min. The wells were rinsed six times with 0.1% Tri-
ton X-100 in PBS, 100   μ  l of 1 mg/ml TMB (3,3    ,5,5    -tetramethylbenzidine 
dihydrochloride; Electron Microscopy Sciences) was added to each well, 
and they were incubated for 15 min. The reaction was stopped by adding 
100   μ  l 2N H  2  SO  4   to each well. Absorbance at 450 nm was read using a 
microplate reader (GENios; Tecan). For Src immunoprecipitation kinase 
assay, the lysates of HCT116 cells transfected with the control or Flag-RIL vec-
tor were incubated with rabbit anti-Src antibody at 4  °  C for 60 min followed 
by incubation with protein A/G  –  agarose beads (Santa Cruz Biotechnol-
ogy, Inc.) for 30 min. The kinase activities of Src immunoprecipitates were 
analyzed as described above. 
Src activation in cancer progression, the identifi  cation of this 
RIL-mediated Src inactivation cycle may also help us to de-
velop novel approaches to control cancer progression. 
  Materials and methods 
  Cells and antibodies 
  HCT116 cells were cultured in McCoy  ’  s 5A supplemented with     L  -  Gln and 
10% FBS. WI-38 cells were cultured with MEM supplemented with 10% 
FBS and     L  -  Gln. Rabbit polyclonal anti-Src, anti-pY416 Src, anti-pY527 Src, 
rabbit anti-FAK, and anti-pY566/577-FAK antibodies were purchased 
from Cell Signaling Technology. A mouse anti-FAK mAb was purchased 
from BD. Anti-Flag mouse mAb (M2) and M2-conjugated agarose beads 
were purchased from Sigma-Aldrich. FITC-conjugated anti  –  mouse IgG and 
Cy3-conjugated anti  –  rabbit IgG antibodies were purchased from Jackson 
ImmunoResearch Laboratories. Alexa Fluor 488  –  conjugated anti  –  mouse 
IgG was purchased from Invitrogen. Mouse mAbs recognizing RIL were 
prepared using a GST fusion protein containing the N-terminal region of 
RIL (residues 1  –  250) as an antigen based on a previously described 
method (  Tu et al., 2003  ). Hybridoma supernatants were initially screened 
for anti-RIL activities by ELISA using recombinant MBP-RIL fusion protein. 
Clones recognizing MBP-RIL in ELISA were selected and further tested by 
Western blotting using MBP-RIL and mammalian cells expressing Flag-RIL. 
  Subcellular localization of RIL and Src 
  Subcellular localization of RIL and Src was analyzed by confocal immuno-
ﬂ  uorescent staining with mouse anti-RIL and rabbit anti-Src antibodies using 
a previously described method (  Gkretsi et al., 2005  ). In brief, cells were 
plated on ﬁ  bronectin-coated coverslips, ﬁ  xed with 4% paraformaldehyde, 
and double stained with mouse anti-RIL and rabbit anti-Src antibodies. The 
mouse and rabbit antibodies were detected with Cy3-conjugated anti  –
  mouse IgG and Alexa Fluor 488  –  conjugated anti  –  rabbit IgG secondary 
antibodies. The samples were mounted in gelvatol and observed at room 
temperature under a confocal microscope (FluoView 1000; Olympus) 
equipped with a 100  ×   NA 1.40 UPLSAPO objective lens. Fluorescence 
emission was collected with internal photomultiplier tubes and analyzed 
using FlowView software (Olympus). 
  RIL expression vector construction, transfection, and immunoprecipitation 
  The formation of the RIL  –  Src complex in mammalian cells was analyzed by 
coimmunoprecipitation. DNA fragments encoding human RIL sequences 
were cloned into the pFlag-CMV-6c vector (Sigma-Aldrich). HCT116 cells 
were transfected with the Flag-RIL expression vectors using Lipofectamine 
Plus (Invitrogen). The expression of Flag-tagged proteins in the transfectants 
was conﬁ  rmed by Western blotting and immunoﬂ  uorescent staining (    70  –
  80% of the transfectants expressed Flag-RIL based on immunoﬂ  uorescent 
staining). For immunoprecipitation analyses, the transfectants were lysed 
with the lysis buffer (1% Triton X-100 in 50 mM Tris-HCl, pH 7.4, containing 
150 mM NaCl, 2 mM Na  3  VO  4  , 25 mM NaF, 1.75% octylglucopyranoside, 
0.1 mM PMSF, 1   μ  M pepstatin, 5   μ  g/ml aprotinin, and 1   μ  g/ml leupeptin). 
The cell lysates were mixed with agarose beads conjugated with anti-Flag 
mAb M2 (Sigma-Aldrich). To immunoprecipitate endogenous RIL from WI-38 
cells, the cell lysates were mixed with anti-RIL mAb 2A2.11 and incubated 
at 4  °  C for 4 h. The samples were then incubated with UltraLink Immobilized 
Protein G (Thermo Fisher Scientiﬁ  c). The beads were washed ﬁ  ve times, and 
the immunoprecipitates were analyzed by Western blotting with antibodies 
as speciﬁ  ed. To prepare anti-FAK immunoprecipitates, HCT116 cells were 
transfected with the Flag-RIL vector or a Flag vector lacking the RIL sequence 
as a control. The 750-  μ  g cell lysates were incubated with 1.25   μ  g anti-FAK 
mAb. Anti-FAK immunoprecipitates were analyzed by Western blotting with 
rabbit antibodies speciﬁ  c for FAK or pY566/577 FAK. 
  RNAi 
  Two previously validated PTPL1 siRNAs (PTPL1 siRNA-1 [Santa Cruz Bio-
technology, Inc.] and -2 [  Dromard et al., 2007  ]) were used to knock down 
PTPL1. HCT116 cells were transfected with PTPL1 siRNA-1, PTPL1 siRNA-2, 
or an irrelevant 21-nucleotide RNA using Lipofectamine 2000 reagent (In-
vitrogen). Depletion of PTPL1 in the PTPL1 siRNA transfectants but not the 
control transfectants was conﬁ  rmed by Western blotting with anti-PTPL1 
anti  body H-300 (Santa Cruz Biotechnology, Inc.). 
  Direct interaction of RIL with Src 
  The direct interaction between RIL and Src was analyzed using afﬁ  nity-
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  Phosphatase assay 
  Phosphatase activities associated with RIL were analyzed using   p  -nitrophenyl 
phosphate as a substrate in an immune complex phosphatase assay as de-
scribed previously (  Pazdrak et al., 1997  ). In brief, HCT116 cells were trans-
fected with vectors encoding Flag-tagged wild-type or mutant forms of RIL or 
Flag vector lacking the RIL sequence as a control. 1 d after the transfection, 
the cells were lysed in the lysis buffer (1% Triton X-100 in 50 mM Tris-HCl, 
pH 7.4, containing 150 mM NaCl, 25 mM NaF, 1.75% octylglucopyrano-
side, 0.1 mM PMSF, 1   μ  M pepstatin, 5   μ  g/ml aprotinin, and 1   μ  g/ml leu-
peptin) and incubated with 30   μ  l of anti-Flag antibody (M2)  –  conjugated 
beads at 4  °  C for 3 h. The beads were washed three times with the lysis 
buffer and three times with the phosphatase buffer (50 mM Hepes, pH 7.2, 
60 mM NaCl, 50 mM KCl, 0.1 mM PMSF, 1   μ  M pepstatin, 5   μ  g/ml apro-
tinin, and 1   μ  g/ml leupeptin). Each sample of the RIL immunoprecipitates or 
the control immunoprecipitates was incubated with 100   μ  l of 5 mM   p  -nitro-
phenyl phosphate in phosphatase buffer containing 1 mg/ml BSA, 10 mM 
DTT, and 5 mM EDTA at 30  °  C. Absorbance at 405 nm was read using a 
GENios microplate reader. 
  Statistical analysis 
  Statistical analysis was performed using the Student  ’  s   t   test. A p-value of   <  0.05 
was considered to be statistically signiﬁ  cant and is indicated in the ﬁ  gures. 
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